Capricor Therapeutics is trading 6.2% lower at $8.40, and the specific catalyst remains unclear. - No confirmed company-specific announcement or report on October 5 explains the move. - Recent clinical-data focus and the upcoming FDA decision are prior context, not a demonstrated cause. - Broader indexes are mixed, with none moving more than 0.5% in the same direction; the provided market context does not establish a market-wide explanation.